title: [A case of giant hepatocellular carcinoma successfully treated by arterial administration of SMANCS].
abstract: A 68-year-old male was referred to our hospital for the precise examination of a giant hepatic tumor detected in a mass survey. The lesion occupied most of the right hepatic lobe, further advancing to the medial segment of the left lobe. However, hepatic functions were well preserved (ICG K = 0.141). Considering the characteristic images of the lesion with positive anti-HCV and high titer of PIVKA II (0.860 AU/ml), the diagnosis was hepatocellular carcinoma. First arterial administration of SMANCS was performed on May in 1994, followed by 6 successive procedures with an interval of about 2 months (total dosage 36 mg), resulting in remarkable tumor shrinkage and tumor marker normalization. On January in 1995, a metastatic lesion to the right rib was controlled by 2 mg of SMANCS administered to the intercostal artery combined with radiation therapy (60 Gray). Frequent administrations of SMANCS caused no serious complications, and tumor feeders were well preserved. Therefore, arterial administration of SMANCS is thought to be one choice for the therapy of giant HCC with good functional reserve.
authors.affiliation: Dept. of Gastroenterology, Sendai City Hospital.
authors.forename: Y
authors.initials: Y
authors.lastname: Yajima
authors.forename: A
authors.initials: A
authors.lastname: Miyazaki
authors.forename: S
authors.initials: S
authors.lastname: Miyasato
authors.forename: Y
authors.initials: Y
authors.lastname: Tomiya
authors.forename: D
authors.initials: D
authors.lastname: Shibuya
authors.forename: S
authors.initials: S
authors.lastname: Ohira
authors.forename: H
authors.initials: H
authors.lastname: Sakurada
authors.forename: K
authors.initials: K
authors.lastname: Ishii
authors.forename: T
authors.initials: T
authors.lastname: Kinoshita
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D003131:Combined Modality Therapy; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008299:Maleic Anhydrides / Q000008:administration & dosage*; D011137:Polystyrenes / Q000008:administration & dosage*; D011878:Radiotherapy; D009353:Zinostatin / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D000970:Antineoplastic Agents; D008299:Maleic Anhydrides; D011137:Polystyrenes; C035755:poly(maleic acid-styrene)neocarzinostatin; D009353:Zinostatin